Drug Research

BioMotiv, a mission-driven pharma company part of The Harrington Project for discovery and development, and Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, announced a strategic collaboration to co-develop therapies. The organizations will form co-owned,...

The new manufacturing facility is designed to have advanced features based on the efficiency of the existing facilities and requires approximately JPY10bn ($90m) in construction costs Japanese pharmaceutical firm Astellas has unveiled plans to construct the Third Fermentation Building as...

CytoviaTherapeutics,a biopharmaceutical company, and the University of California,San Francisco(UCSF) announced that they have entered a 3-year research partnership to develop novel precision gene editing to improve the performance, safety and persistence of Natural Killer(NK) cells and Chimeric Antigen Receptor(CAR)-NK...

Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer...

VBI Vaccines Inc. (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported top-line data from CONSTANT, the second pivotal Phase 3 study, assessing lot-to-lot manufacturing consistency of Sci-B-Vac®, the company’s trivalent hepatitis B (HBV) vaccine,...

Generation Bio, a company leading a new generation of gene therapy, announced the closing of a $110 million Series C financing. Proceeds will be used to advance the company’s two lead liver-targeted programs for hemophilia A and phenylketonuria (PKU)...

Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia’s proprietary AI drug discovery platform and drug design know-how with...